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Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare tumors that present
many clinical features secreting peptides and neuroamines that cause distinct clinical syn-
dromes such as carcinoid syndrome. However most of them are clinically silent until late
presentation with mass effects. Surgical resection is the first line treatment for a patient
with a GEP-NET while in metastatic disease multiple therapeutic approaches are possible.
GEP-NETs are able to express somatostatin receptors (SSTRs) bounded by somatostatin
(SST) or its synthetic analogs, although the subtypes and number of SSTRs expressed
are very variable. In particular, SST analogs are used frequently to control hormone-related
symptoms while their anti-neoplastic activity seems to result prevalently in tumor stabiliza-
tion. Patients who fail to respond or cease to respond to standard SST analogs treatment
seem to have a response to higher doses of these drugs. For this reason, the use of higher
doses of SST analogs will probably improve the clinical management of these patients.
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INTRODUCTION
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are
characterized by an yearly incidence of 1.2–3.0 cases/100,000
inhabitants (1–5). The majority of the GEP-NETs are sporadic but
they can be also part of familiar syndromes such as MEN 1 syn-
drome, von Hippel–Lindau disease, and neurofibromatosis type 1
while the clinical characteristics depend on the site of the primary
tumor and its ability to secrete neuroamines and peptides. Among
functioning tumors, major clinical entities are represented by
carcinoid syndrome, hypoglycemic syndrome, Zollinger–Ellison
syndrome, WDHA (Water Diarrhea–Hypokalemia–Achlorydria)
syndrome, and glucagonoma syndrome. However most of the
GEP-NETs are not able to produce biologically active hormones
(non-functioning tumors) and therefore the diagnosis is often
made too late only for the presence of symptoms due to the
mass effect and/or metastases, mainly hepatic (1). In patients with
localized well-differentiated neuroendocrine carcinomas, 5-year-
survival is 60–100% while with regional disease or distant metas-
tases 5-year-survival is 40 and 29%, respectively (6). Around 80%
of GEP-NETs express somatostatin receptors (SSTRs); they are five
different G-protein coupled receptor subtypes (SSTRs 1–5) that
are differently expressed in the various types of tumor (Tables 1
and 2). It is important to underline that SSTRs are present not
only in neoplastic tissues. For example Beneyto and co-workers
used in situ hybridization to quantify the mRNA expression lev-
els of SST receptors subtype 1 (SSTR1) and subtype 2 (SSTR2)
in dorsolateral prefrontal cortex area 9 from 23 matched pairs
of subjects with schizophrenia and normal comparison subjects.
SSTR1 mRNA levels did not differ between subject groups while
mean cortical SSTR2 mRNA levels were significantly 19% lower
in the subjects with schizophrenia (7). Moreover in a very inter-
esting and complete work, Pasquali and co-workers, reported that
the radiolabeled somatostatin (SST) analog octreotide accumu-
lates within the orbits of active Graves’ ophthalmopathy (GO),
and octreotide and lanreotide have been proposed to treat this
disorder. In particular, the authors described the expression of
SST1–5 genes in lymphocytes recovered from retroorbital tissues
obtained from patients with GO undergoing orbital decompres-
sion. All SSTs transcripts were found in lymphocytes both from
GO retroorbital tissues and blood samples (8). In addition, recent
studies have shown that SSTRs are preferably expressed in well-
differentiated neoplasia and some advanced forms loose particular
receptor subtypes while keeping others (9, 10); SSTRs subtypes
can form homo/heterodimers at the membrane level, developing
new receptors with different functional features (11), and that
this receptor dimerization may be induced by addition of either
dopamine or SST (Figure 1). In a study examining 81 function-
ing and non-functioning GEP-NETs the large part of the tumors
expressed SSTRs 1, 2, 3, and 5, while SSTR 4 was detected only
in a small minority (12). SSTRs have been extensively mapped in
different pancreatic tumors by means of autoradiography, reverse-
transcription polymerase chain reaction, in situ hybridization, and
immunohistochemistry; SSTRs 1, 2, 3, and 5 are usually expressed
in pancreatic NETS in particular insulinomas had heterogeneous
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Table 1 | Somatostatin receptorsa in neuroendocrine
gastroenteropancreatic tumors (%).
SSTR1 SSTR2 SSTR3 SSTR4 SSTR5
All 68 86 46 93 57
Insulinoma 33 100b 33 100 67
Gastrinoma 33 50 17 83 50
Glucagonoma 67 100 67 67 67
VIPoma 100 100 100 100 100
N-F 80 100 40 100 60
IP, vasoactive intestinal polypeptide; N-F, non-functioning.
aUsing receptor subtype antibodies.
bMalignant insulinoma.
Modified from Oberg et al. (15).
SSTRs expression while 100% of somatostatinomas expressed
SSTR 5 and 100% of gastrinomas and glucagonomas expressed
SSTR 2 (13). SST is a natural peptide hormone secreted in var-
ious parts of the human body, including the digestive tract, able
to inhibit the release of numerous endocrine hormones, including
insulin, glucagon, and gastrin. The biological effects of SST are
mediated through its specific receptors (SSTRs 1–5) all bind nat-
ural peptides (SST-14, SST-28, and cortistatin) with similar high
affinity. However, endogenous SST short half-life in circulation (1–
3 min), makes it difficult to use it continuously and has resulted in
the development of synthetic analogs from the early 1980s when
a number of short synthetic analogs of SST including SMS201-
995 (octreotide), RC-160 (vapreotide), BIM 23014 (lanreotide),
and MK 678 (seglitide) were developed. These cyclic octapep-
tides are more resistant to peptidases and their half-lives and
hence their biological activities are substantially longer than native
SST (1.5–2 h vs. 1–2 min) (14). Moreover the development of a
depot formulation of octreotide [octreotide long-acting repeat-
able (LAR)], administered up to 30 mg once every 4 weeks has to a
large extent eliminated the need for daily injections. Lanreotide SR
(slow release) 30, 60, and 90 mg formulations administered every
10–14 days, has a similar efficacy to octreotide in the treatment
of carcinoid tumors (15). A new slow release depot preparation
of lanreotide, lanreotide autogel, is administered subcutaneously
up to 120 mg once a month (16). Native SST and its synthetic
analogs show different affinity for the five specific SSTRs (11, 12,
17). Native SST binds all the five receptor subtypes (SSTRs 1–5).
The effects of the SST analogs are mediated by the interaction
with SSTR 2 and 5 receptors while the new SST analog, pasireotide
(SOM 230), shows higher binding capacity toward SSTRs 1, 2, 3,
and 5 with no agonist activity at the type 4 receptor (17) (Table 3).
Moreover, in vitro studies demonstrated that SOM 230 was more
effective than octreotide to control cell proliferation and apoptosis
(18). The different receptor subtypes binding affinities seems to
result in different biological and clinical activities (12).
THE SYMPTOMATIC AND BIOCHEMICAL EFFECTS OF SST
ANALOGS
Gastroenteropancreatic neuroendocrine tumors first line ther-
apy, where possible, is always an aggressive surgical approach,
aimed to obtain a curative tumor ablation, even in the presence
Table 2 | Somatostatin receptor subtypes mRNA in neuroendocrine
tumors.
Tumor SST1
(%)
SST2
(%)
SST3
(%)
SST4
(%)
SST5
(%)
Gastrinoma 79a 93 36 61 93
Insulinoma 76 81 38 58 57
Non-functioning pancreatic tumor 58 88 42 48 50
Carcinoid tumor of the gut 76 80 43 68 77
SST, somatostatin receptor.
aIndicates the percentage of positive tumors for each SSTRs mRNA expression
may overestimate the number of receptors present, depending on the technique
used (PR-polymerase chain reaction, Northern blot, in situ hybridization).
Modified from Plockinger (19).
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FIGURE 1 | Somatostatin/dopamine chimera-induced dimerization of
somatostatin and dopamine receptors [Adapted from Ref. (11)].
of metastatic disease. However, in patients with functioning or
metastatic tumors, the treatment goal is to improve their quality of
life trying to alleviate the tumor associated symptoms and increas-
ing survival (2, 14, 15). Recently, the diagnostic and therapeutic
approach of GEP-NETs has considerably improved, mainly due to
better imaging techniques (CT, MRI, PET) and SST analog-based
imaging methods, as well as receptor subtype characterization
and the introduction of long-acting SST analogs (21–27). Usu-
ally, the treatment with long-acting preparations of SST analogs
consists in an intramuscular injection (i.m.) every 2 or 4 weeks
(octreotide-LAR, 10–30 mg; lanreotide autogel 60–120 mg) and
the efficacy in the control of symptoms is well-documented (2, 14,
15), even if patients with islet cell tumor often show a transient
(median time 2.5 months) and non-significant response (21–27).
The drugs are safe and well-tolerated in both long- and short-term
treatments (28–32). However, after 9–12 months, drug resistance
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Table 3 | Somatostatin receptor subtype-binding affinity of
somatostatin analogs.
Compound SSTR1 SSTR2 SSTR3 SSTR4 SSTR5
RECEPTOR SUBTYPE AFFINITY (IC50, nM)
Somatostatin-14 2.26 0.23 1.43 1.77 0.88
Somatostatin-28 1.85 0.31 1.3 ND 0.4
Octreotide 1140 0.56 34 7030 7
Lanreotide 2330 0.75 107 2100 5.2
Pasireotide 9.3 1 1.5 >100 0.16
ND, not determined.
Modified from Ref. (20).
should appear and patients may show the symptoms of recrude-
scence. In such cases the approach proposed was to continue
the treatment by increasing the analog dosage or by shortening
the administration range (33). A randomized double-blind trial
compared long-acting octreotide-LAR at 10, 20, and 30 mg every
4 weeks with open-label short-acting octreotide every 8 h for the
treatment of carcinoid syndrome. It showed that the efficacy of
short-acting octreotide and of the long-acting octreotide-LAR
was the same once circulating octreotide steady-state concentra-
tions were achieved (34). O’Toole et al. in a multicentre study
on 33 patients with the carcinoid syndrome comparing the treat-
ment with lanreotide (30 mg i.m. every 10 days) vs. octreotide
(200µg s.c. twice or thrice daily) founded no significant differ-
ences in controlling symptoms (53.8 and 45.4%, respectively).
Lanreotide and octreotide may also significantly lower the lev-
els of the catabolite of serotonin (urinary 5-hydroxyindoleacetic
acid/5-HIAA) (35). Ruszniewski et al. evaluated the efficacy and
safety of the 28-day-aqueous prolonged release formulation of
lanreotide in 75 patients in a 6-month-dose titration study where
30% of patients showed a biochemical response and 75 and 80%
of patients reported resolution of diarrhea and flushing, respec-
tively. The median decrease in levels of urinary 5-HIAA and serum
chromogranin A was 24 and 38%, respectively (36). An interim
analysis of a phase II trial of SOM230 in 21 patients with metastatic
carcinoid tumors whose symptoms (diarrhea and flushing) were
refractory/resistant to octreotide-LAR showed symptom relief in
33% (37). Approximately 10–15% of patients with midgut car-
cinoids suffer from watery diarrhea, flushing, right-sided heart
failure, and bronchial constriction (carcinoid syndrome), due to
the tumor hypersecretion of a variety of endocrine substances, the
most frequent of which are serotonin (5-hydroxytryptamine) and
the tachykinins (38, 39), and therefore SST analogs are impor-
tant palliative tools for these patients. In insulinoma it has been
noted that octreotide treatment may induce hypoglycemia worse
in those patients lacking SSTRs 2 and 5, and as glucagon secre-
tion is also inhibited, patients have to be observed closely at the
beginning of therapy to prevent severe hypoglycemia due to the
reduced glucagon-dependent counter-regulation (19). Hence, this
treatment has to be started in a hospital setting, and should be
reserved only for the minority of insulinoma patients with positive
imaging on SRS. Vezzosi et al. recently assessed that octreotide was
effective in the control of hypoglycemia in more than 50% of the
insulinoma patients (40). The treatment was effective in all SSTR 2
positive patients and in a few SSTR 2 negative ones, while no rela-
tion between treatment effectiveness and the expression of SSTR
5 was observed (40). These results are in concordance with other
case reports and smaller series of insulinoma patients reported
in the literature (41–45). In glucagonoma patients SST analog
treatment is indicated to reduce the symptoms related to the char-
acteristic skin rash (necrolytic migratory erythema) or diarrhea
(46–50). Somatostatinomas symptoms are due to SST hypersecre-
tion (hyperglycemia, cholelithiasis, diarrhea and steatorrhea, and
hypochlorhydria) or to the mass effect (51). Although it seems a
paradox to treat patients with symptoms related to elevated SST
levels with a somatostatinoma, in 1998 Angeletti et al. showed that
octreotide treatment was effective in reducing SST plasma lev-
els and improving the related symptoms in three patients with
metastatic somatostatinomas (52). Furthermore, nine cases of
VIPoma have been described in which octreotide was very suc-
cessful as adjuvant therapy for symptoms control and for reducing
the serum elevated VIP levels by improving the diarrhea and the
electrolyte imbalance (53–55).
THE ANTI TUMOR EFFECTS OF SST ANALOGS
The anti-neoplastic activity of SST analogs has been demonstrated
in several experimental models in vivo and in vitro (56–61) but it
is still little known regarding the anti-proliferative role of SSA
in GEP-NETs, although increasing data suggest that such analogs
can be tumoristatic, at least in some circumstances (62). The anti-
neoplastic action of SST analogs depends on the kind of tumor
and the receptor subtypes to which they are bound to and occurs
through direct and indirect mechanisms. While direct activities
are mediated by specific membrane receptors and include antimy-
totic and apoptotic effects, indirect effects do not depend on the
receptor binding but depend on the growth factor inhibition,
antiangiogenic, and immuno-modulating activities. SST analogs
are able to inhibit the growth of Swarm chondrosarcoma, used as
experimental model of SSTR free tumor (63). The mitosis inhi-
bition is mediated by SSTRs 2 and 5 and results in the cell cycle
arrest (56). The loss of the SSTR 2 expression in some human
adenocarcinomas seems to be responsible for loosing the regu-
lation of cell proliferation (10–19, 21–64). The loss of SSTR 2
may consequently promote tumor growth and make it clear the
therapeutic inefficacy of SST analogs in such kind of neoplasia.
Apoptosis seems to be induced by two different processes: interac-
tion with the SSTR 3 (57) and inhibition of the Insulin-like Growth
Factor I (IGF I), known as a potent antiapoptotic hormone (65).
The pro-apoptotic activity of SST analogs seems to have clini-
cal relevance, as shown by the interesting findings published by
Eriksson et al. that reported an increase in apoptosis in bioptic
samples of tissues by patients with GEP-NETs after the treatment
with SST analogs at high doses. It followed that apoptosis is related
to the biochemical response and the disease stabilization (70% of
cases) (66, 67). However, Faiss et al. observed an overall response
rate (ORR) of 6.7%, comparable to that recorded at conventional
doses (68), in 24 patients with GEP-NETs treated with high doses
of lanreotide (15 mg/day). The indirect anti-proliferative efficacy
of SST analogs is shown by an antiangiogenic mechanism. Tumor
angiogenesis is essential in the development and metastatic spread
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of tumors, so the growth can be actually controlled by reduc-
ing the vascularization of the neoplastic tissue. In experimental
models, octreotide shows a strong antiangiogenic effect, which is
probably mediated by the inhibition of the Vascular Endothelial
Growth Factor (VEGF) (69–71). The treatment with octreotide
would result in a significant reduction in VEGF levels compared
to the baseline, since it is related to the survival of the patients (71).
It was observed that endothelial cells do not express the SSTR 2
that is present on the contrary, when they proliferate in order to
form blood vessels. This could represent further opportunity to
treat patients with octreotide that is able to recognize and inhibit
new vessel formation both alone and with other drugs, thanks to its
high affinity with such receptor (Table 3). Immunomodulation is
another indirect mechanism of action of SST analogs. Preliminary
evidence suggests that they stimulate the production of immune
system components with antitumor effect, such as natural killer
cells (72, 73), even if up to now it is not clear whether this can
be clinically significant thus helping the antitumor efficacy of SST
analogs. Few data exist on the functions mediated by the SSTR 4.
However, no unanimity exists about the SST analog ability to con-
trol (i.e., to slow) the tumor progression. In vitro studies reported
that the response of different cell lines to the octreotide exposition
produces a biphasic dose–response curve (74, 75). Consequently,
overdose or underdose of SST analogs may result in a suboptimal
anti-neoplastic activity. Nevertheless, the negative results of some
clinical studies in terms of tumor response could be due to the
administration of too low doses to achieve receptor optimal satu-
ration. After all, in other studies that used octreotide doses higher
than 8 mg/day and lanreotide doses higher than 10 mg/day (76),
no improvement of the SST analog antitumor effect was observed.
No study on the tumor response monitored plasma levels of an
SST analog up to now, in order to assess that optimal drug thera-
peutic levels are reached but not exceeded (77). Tumor shrinkage
was demonstrated in <10% of the patients. However, a stabiliza-
tion of tumor growth occurs in up to 50% of the patients with
neuroendocrine tumors of various locations. Stable disease was
observed in 37–45% of the patients with documented tumor pro-
gression before SSA therapy (Table 4). The median duration of
stabilization was 26.5 months (31, 78–81). In a study on a selected
group of patients with progressive disease, in the 47% of cases
was demonstrated a stable disease when treated with a high dose
of lanreotide (3–5 g/day) (82). This result has been confirmed in
patients with advanced midgut carcinoids, who had a stabiliza-
tion of the disease for 6–24 months in the 75% of cases (83). One
patient with a pancreatic primary tumor and distant extrahepatic
metastases, showed a poor response to treatment in multivariate
analysis. Age, size of the primary tumor, and Ki67 did not influence
the response rate to SSA therapy (81). A stabilization of the disease
was maintain throughout long-term follow-up in patients who
achieve it after 6 months of treatment; these patients live longer
than those unresponsive to therapy (81, 84). Very recently, Rinke
et al performed for the first time a placebo-controlled, double-
blind, and phase III B study in 85 patients with well-differentiated
metastatic midgut NETs using octreotide-LAR 30 mg intramuscu-
larly in monthly intervals (PROMID study). Median time to tumor
progression in the octreotide-LAR and placebo groups was 14.3
and 6 months, respectively. After 6 months of treatment, stable
disease was observed in 66.7% of patients in the octreotide-LAR
group and 37.2% of patients in the placebo group. Functionally
active and inactive tumors responded similarly. The most favorable
effect was observed in patients with low hepatic tumor load and
resected primary tumor. Octreotide-LAR significantly lengthened
the time to tumor progression compared with placebo in patients
with functionally active and inactive metastatic midgut NETs (85).
Midgut carcinoids express SSTRs in 80–100% of cases and SSTR
2 is the most frequently expressed (39). The anti-proliferative
effect of SST analogs on the growth of the midgut carcinoids
is unknown. A partial or complete responses were observed in
<10% of the patients, while stabilization of tumor growth was
noticed in 24–57% of the patients (6). Few data are available
regarding the role of SST analogs in the treatment of gastrino-
mas. In a study of 15 malignant gastrinoma, in about 50% of
these patients, octreotide had an anti-proliferative effect, includ-
ing one patient with tumor regression and seven patients with
tumor stabilization (mean period 25 months) patients (86). The
long-acting SST analog octreotide-LAR was administered in a
patient with multiple type A gastric carcinoids for a period of
9 months with a normalization of serum gastrin levels and per-
manent disappearance of the tumor (87). Fykse et al. treated five
patients with hypergastrinemia and gastric carcinoids for a period
Table 4 | Anti-proliferative effect of somatostatin analogues in patients with progressive disease.
SSA Dosagen n CR PR SD PD Reference
Lanreotide 3000µg/day 22 0 1 7 14 (93)
Lanreotide 30 mg/2 weeks 35 0 1 20 14 (91)
Octreotide 600/1500µg/day 52 0 0 19 33 (75)
Octreotide 1500/3000µg/day 58 0 2 27 29 (28)
Lanreotide 15000µg/day 24 1 1 11 11 (93)
Octreotide 600µg/day 10 0 0 5 5 (74)
Octreotide median dose of 250µg three times daily 34 0 1 17 0 (76)
Octreotide-LAR 30/lanreotide SR 60 mg/28 days 31 0 0 14 4 (77)
Total 256 1 6 115 105
Percentage (%) 0.3 2 45 41
CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease.
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of 1 year with monthly injections of octreotide-LAR with a signif-
icant reduction in tumor load, entero-chromaffin-like cells (ECL)
cell density, and normalization of circulating chromogranin A
levels, indicating a possible direct anti-proliferative effect of the
treatment (88). These results suggest that the SST analogs could
have an important anti-proliferative effect. However, data on the
effect of SST analogs on tumor growth in patients with gastric
carcinoids type C or poorly differentiated endocrine carcinomas
are scanty. In poorly differentiated gastric carcinomas, treatment
with SST analogs is not considered. As surgical excision is the
definitive treatment of insulinoma, there are few contrasting data
in the literature regarding the inhibitory effect of the SST analogs
on the growth of these tumors. Grozinsky-Glasberg et al. have
conducted a study regarding the effects of SST analogs on cell
proliferation in the rat-derived insulinoma cell line (INS1). Their
preliminary data show that octreotide has a significant inhibitory
effect on cell proliferation, as assessed by cell counting and MTS
assay, and on phosphorylation states of a number of proteins
in the PI3K/Akt/mTOR pathway (89, 90). In his work, Vezzosi
founded that despite achieving hypoglycemic control, insulinoma
size remained unchanged or increased moderately despite nor-
mal blood glucose levels, concluding that SST analogs, as medical
treatment is not sufficient to prevent tumor growth in patients
with malignant insulinomas (40). In 2006, Romeo et al. reported
a complete clinical remission with regression of the metastatic
lesions in the liver after 1 year in a patient affected by metastatic
insulinoma with severe hypoglycemia treated with octreotide-LAR
(90). A more controversial area concerns the treatment of patients
with non-functioning endocrine tumors of the pancreas as few
studies have been published in these patients. The prospective
German Sandostatin multicentre phase II trial investigated the
effects of octreotide for 1 year on tumor growth in 103 patients
and included 15 patients with diagnosed non-functional pancre-
atic tumors (79). Only 3 out of these 15 patients had a stable
disease, in 8 patients a tumor progression occurred while the out-
come of the remaining 4 patients was not clear. As previously
reported, the SST analog efficacy depends on the tumor recep-
tor expression patterns, but these are rarely assessed, even if there
is evidence of better results on survival obtained with selective
treatments. An anti-proliferative effect was achieved on hepatic
metastatic cells in a patient with a carcinoid tumor, selected for
the treatment with SST analogs after the immunohistochemi-
cal identification of the SSTRs 1, 2, and 5 subtypes expression
on the neoplastic cell surface (91). A complete clinical remis-
sion with regression of the metastatic lesions in the liver after
1 year of treatment was observed in a patient affected by metastatic
insulinoma with severe hypoglycemia treated with octreotide-LAR
expressing at immunohistochemical analysis of tissue specimens
a strong membrane immunoreactivity for SSTR 2 in both the pri-
mary nodule and the metastases (90). However, another study
showed neither an anti-neoplastic effect nor an increase in sur-
vival percentage of treated patients (92). It has been reported
that in glucagonoma patients there are no data available on their
SSTR expression patterns (49). In 2006 we demonstrated, for the
first time, a scattered immunopositivity for SSTRs in a case of
malignant glucagonoma. We had access to polyclonal antibod-
ies specifically targeted against SSTR5 and SSTR2 and we were
therefore able to localize these two receptors in our histological
sections. The immunopositivity was detected for both receptor
subtypes in the membrane and in the cytoplasm of glucagonoma
cells. We then treated our patient with a combination therapy con-
sisting of the SST analog octreotide and interferon-a. The patient
had a complete resolution of skin rash, normalization of plasma
glucagon, chromogranin A, and neuron specific enolase levels and
a metastatic disease stabilization. The patient’s quality of life sig-
nificantly improved, and she was alive 40 months after debulking
surgery (50).
THE EFFECTS OF HIGHER THAN USUAL DOSE OF SST
ANALOGS
It was suggested that higher than usual dose of SST analogs treat-
ments (>3.000µg/day) may promote the anti-proliferative effect,
especially in those patients responding to standard doses (2, 17,
18, 83, 94, 95). A high-dose treatment with lanreotide (up to
12 mg/day) produced tumor size reduction in 5% and stabilization
in 70% of the 19 patients. An induction of apoptosis in the tumors
was observed in responding patients, a phenomenon not seen with
regular doses of SST analogs, but often produced by chemother-
apeutic agents (67). Subcutaneously injections of 5 mg lanreotide
three times a day for a period of 1 year produced one complete
and one partial remission (PR) in 30 patients with functional
midgut NETs; stable disease in 11 patients (36%) and progres-
sion of the disease after 3–12 months of treatment in 11 patients
(68). The treatment with high-dose SST analogs induced apop-
tosis in neuroendocrine tumors, while this was not found during
treatment with low-dose SST, in a study where biopsy specimens
were taken before and during SST analog treatment (66). In a
highly select group of patients with progressive disease, 47% of
the patients demonstrated at least stable disease when treated with
a high dose of lanreotide (3–5 g/day) (82). High-dose formula of
octreotide has been recently reported to stabilize hormone pro-
duction and tumor growth in 75% of patients with advanced
midgut carcinoid tumors and progressive disease with stabiliza-
tion for 6–24 months (83). These effects may be attributable to
SSTR 2, which is the most frequently expressed subtype and/or
SSTR 5, 1, and 3 that are also expressed (96, 97). Data from
a study with ultra-high-dose octreotide pamoate (Onco-LAR;
Novartis) at 160 mg intramuscularly every 2 weeks for 2 months
followed by the same dose once monthly, appear to show some
promise. Tumor size stabilization was obtained in 12 patients,
a biochemical responses in 9 patients and/or stability in 11. No
significant tumor reduction was noted. At 6 months, the median
plasma concentrations of octreotide were 25–100 times higher
than those obtained by using octreotide-LAR at regular doses. A
significant inhibition of angiogenesis was also showed through
the down-regulation of proliferative factors such as VEGF and
fibroblast growth factor (14). The highest response rates were
reported using octreotide in doses >30 mg/day or lanreotide in
doses >5 mg/day (and up to 15 mg/day) (64). Tomassetti et al.
have reported that after 1-year therapy, the tumor completely dis-
appeared in three patients suffering from gastric carcinoid, two
of whom were treated with lanreotide 30 mg i.m. every 10 days
(98). In a recent paper it was reported that in patients with
Hashimoto’s thyroiditis presenting ECL hyperplasia, considered a
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pre-neoplastic mark, the treatment with SST analog for 12 months
resulted into the disappearance of ECL lesions (93). SST analogs
can have a role in the treatment of digestive neuroendocrine
tumors with low grades of malignancy, a low cellular prolifera-
tion index and high specific receptorial density in vivo as reported
by Bombardieri et al. (29). In a very complete and well design
paper of Ferolla et al. patients with well-differentiated neuroen-
docrine tumors, were treated with long-acting octreotide (LAR),
conventionally administered at a dose of 30 mg every 28 days; the
end point of this study was to evaluate a different schedule of
octreotide-LAR administration consistent with a shorter interval
between administrations (21 days) in patients with a progressive
disease at standard-dose interval. For this reason 28 patients who
had tumor progression during therapy with LAR 30 mg every
28 days were enrolled. Clinical, biological, and objective tumor
response was evaluated after LAR 30 mg every 21 days. Time to
progression was also evaluated after LAR 30 mg every 21 days
and compared to LAR 30 mg every 28 days. The treatment with
LAR 30 mg every 21 days resulted in complete and partial con-
trol of clinical symptoms in 40 and 60% of cases, respectively.
Circulating neuroendocrine markers were significantly decreased
in 30% of cases. A stabilization of disease was obtained in 93%
and objective response in 7%. The median time to progression
was significantly longer by using the shortened interval of LAR
administration as compared to the standard one (30 vs. 9 months,
p< 0.0001) and the treatment was safe and well-tolerated. The
authors conclude that the shortened schedule of LAR admin-
istration was able to re-institute control of clinical symptoms,
to decrease level of circulating neuroendocrine markers and to
increase time to progression in patients previously escaping from
a standard schedule treatment (99).
SOMATOSTATIN ANALOGS AND DIAGNOSTIC/THERAPEUTIC
NUCLEAR MEDICINE
Somatostatin receptors are able to form a receptor–ligand com-
plex permitting the internalization and the accumulation of the
radiopharmaceutical peptide inside the tumor using this proce-
dures for diagnosis and radiometabolic treatments of these tumors
(Figure 2). Peptide-receptor radionuclide therapy (PRRT) is an
important treatment strategy for tumors that express adequate
densities of SSTRs and has proven to be safe and effective. It
was initially performed using indium-111 (24, 100). Recently, the
development of SST peptides with higher receptor affinity conju-
gated with radio-metal labeling chelators, such as DOTA, which
may be allow stable labeling with gallium, yttrium, or lutetium,
changing the affinity profile for particular subtypes of SSTRs can
permit new therapeutic options (101). Waldherr et al. evaluated
the tumor response to targeted irradiation with the radiolabeled
SST analog 90Y-DOTATOC in 41 patients with GEP-NET and
bronchial tumors. They reported an ORR of 24%. For endocrine
pancreatic tumors it was 36%. A complete remission was found in
2%, a PR in 22%, a minor response in 12%, stable disease in 49%,
and progressive disease in 15% of patients. The treatment was well-
tolerated and there was a significant reduction of symptoms and
the 2-year survival time was 76± 16% (102). 177Lu DOTATATE
[177Lu]DOTA-Tyr(3)-octreotate, a selective analog of SSTRs 2,
in spite of its favorable affinity profile, at its maximum tolerated
dose, it is limited by toxic effects on the kidney and bone marrow.
FIGURE 2 | PET gallium 68 DOTATOC showing the presence of multiple liver metastasis from neuroendocrine ileal tumor.
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Nevertheless, the results seem encouraging compared with histori-
cal therapeutic data (103). Kwekkeboom et al. obtained promising
results using 177Lu DOTATATE [177Lu]DOTA-Tyr(3)-octreotate
in 131 patients with NETs. A complete remission was observed
in 2% of patients, a PR in 26%, a minor response in 19%, stable
disease in 35%, and progressive disease in 18% of patients. Higher
remission rates were positively correlated with high uptake on
pre-therapy SSTRs imaging, whereas progressive disease was sig-
nificantly more frequent in patients with extensive disease. Median
time to progression was more than 36 months (24). The combi-
nation of 90Y- and 177Lu-labeled analogs (104) seems to have had
superior antitumor effects when compared with either 90Y- or
177Lu-analog in animals presenting with tumors of various sizes.
It has been reported that 177 Lutetium may be more effective for
smaller tumors whereas 90Yttrium may be more effective for larger
tumors (105, 106).
SOMATOSTATIN ANALOGS AND INTERFERON
The combination of SSAs and interferon (IFN) has been used in
an effort to enhance the anti-proliferative effect of IFN therapy, to
add the positive effect of SSAs on hypersecretory syndromes, and
to reduce the dose of IFN and thus the number of IFN-related side-
effects. Whether SST analogs and IFN show a synergistic effect on
tumor growth and in carcinoid syndrome symptom management
is matter of debate. The combination therapy with SST analogs
and IFN is in fact limited by the small number of trials, with vari-
able results. This combination seems of benefit in patients where
the usual octreotide treatment failed to achieve a biochemical and
symptomatic control (107).
CONCLUSION
Neuroendocrine tumors of the gastroenteropancreatic (GEP-
NETs) system comprise a rare group of malignant neoplasms. The
SST analogs have been shown to be very useful for symptomatic
and biochemical improvement in patients with these tumors while
preclinical and clinical studies provide conflicting results on their
antitumor effects. The mechanisms of these effects are unknown,
but probably are in part due to direct effects on proliferative signal-
ing pathways, activation of apoptosis, and effects on angiogenesis.
Biological response to SST analogs depends on distribution and
level of expression of SSTRs subtypes in tumors, and the expres-
sion of selective SSTR-signaling pathway molecules. The high
density of SSTR 2 in endocrine tumors explains the use of SSTR
2 specific analogs in the diagnosis and treatment of these tumors.
However, the role of SSTR 1, 3, and 5 appears to be of increasing
interest. The development of new peptidic and non-peptidic SST
analogs, subtype selective agonists, chimeric analogs, or pan-SST
analogs will probably improve the diagnosis and treatment of GEP-
NETs, which express SSTRs other than SSTR 2. The combination
of SSAs and IFN seems of benefit in patients where the treatment
with SST analogs alone failed to achieve a biochemical and symp-
tomatic control while their synergistic effect on tumor growth
is still unknown. The analysis of the SSTR status specifically for
each patient, and studies of individual tumor biological behavior,
might be of therapeutic interest and could help to optimize treat-
ment especially in unresectable tumors. Peptide-receptor-targeted
radiotherapy for advanced disease using radiolabeled octapeptide
analogs appears to be a significant progress in the treatment
of GEP-NETs but data are limited, mainly about the best time
for its administration, or what is the most appropriate radioli-
gand/combination to be used for each patient, and if and how
the doses should be fractionated. Novel strategies based on SSTR
2 receptor gene transfer to target tumor growth and angiogenesis
might offer new prospectives of therapeutic interest mainly to treat
unresectable tumors. Prospective studies including large number
of patients regarding the optimal dosage and modes of adminis-
tration of SST analogs and the development of new slow release,
SSTR subtype specific compounds are needed.
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